NZ628079A - Extended-release formulation for reducing the frequency of urination and method of use thereof - Google Patents
Extended-release formulation for reducing the frequency of urination and method of use thereofInfo
- Publication number
- NZ628079A NZ628079A NZ628079A NZ62807913A NZ628079A NZ 628079 A NZ628079 A NZ 628079A NZ 628079 A NZ628079 A NZ 628079A NZ 62807913 A NZ62807913 A NZ 62807913A NZ 628079 A NZ628079 A NZ 628079A
- Authority
- NZ
- New Zealand
- Prior art keywords
- urination
- extended
- frequency
- reducing
- release formulation
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000013265 extended release Methods 0.000 title abstract 2
- 230000027939 micturition Effects 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 2
- 239000000730 antalgic agent Substances 0.000 abstract 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 abstract 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 abstract 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 abstract 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 abstract 1
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract 1
- 239000002160 alpha blocker Substances 0.000 abstract 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 abstract 1
- 229960001389 doxazosin Drugs 0.000 abstract 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 abstract 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 abstract 1
- 229960004039 finasteride Drugs 0.000 abstract 1
- 229960001680 ibuprofen Drugs 0.000 abstract 1
- 229960000905 indomethacin Drugs 0.000 abstract 1
- 229960004270 nabumetone Drugs 0.000 abstract 1
- 229960003940 naproxen sodium Drugs 0.000 abstract 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 abstract 1
- 229960005489 paracetamol Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method for reducing the frequency of urination is disclosed. The method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents selected from aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, and one or more α-blockers or 5α-reductase inhibitors such as doxazosin or finasteride. In one embodiment, the one or more analgesic agents are formulated for extended-release.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ714662A NZ714662A (en) | 2012-03-19 | 2013-03-14 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/424,000 US8236857B2 (en) | 2010-07-08 | 2012-03-19 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US13/487,348 US20120244221A1 (en) | 2010-07-08 | 2012-06-04 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| PCT/US2013/031617 WO2013142274A1 (en) | 2012-03-19 | 2013-03-14 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ628079A true NZ628079A (en) | 2016-05-27 |
Family
ID=49223209
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ718163A NZ718163A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| NZ630471A NZ630471A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| NZ712594A NZ712594A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| NZ714288A NZ714288A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| NZ628079A NZ628079A (en) | 2012-03-19 | 2013-03-14 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| NZ714662A NZ714662A (en) | 2012-03-19 | 2013-03-14 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ718163A NZ718163A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| NZ630471A NZ630471A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| NZ712594A NZ712594A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| NZ714288A NZ714288A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ714662A NZ714662A (en) | 2012-03-19 | 2013-03-14 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP2827852A4 (en) |
| JP (5) | JP2015510928A (en) |
| KR (4) | KR20140134333A (en) |
| CN (4) | CN104302284A (en) |
| AU (4) | AU2013235518B2 (en) |
| BR (2) | BR112014020271A8 (en) |
| CA (2) | CA2866853A1 (en) |
| HK (3) | HK1251469A1 (en) |
| MX (3) | MX2014011128A (en) |
| MY (2) | MY174090A (en) |
| NZ (6) | NZ718163A (en) |
| RU (3) | RU2669565C2 (en) |
| SG (2) | SG11201500408VA (en) |
| WO (2) | WO2013142197A1 (en) |
| ZA (2) | ZA201405862B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10596127B2 (en) | 2013-03-14 | 2020-03-24 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
| KR20240015735A (en) | 2013-07-23 | 2024-02-05 | 세레니티 파마슈티컬즈 엘엘씨 | Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist |
| RU2016152226A (en) * | 2014-06-06 | 2018-07-09 | УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Pharmaceutical composition for reducing the frequency of urination and method for its use |
| KR101809908B1 (en) | 2014-07-21 | 2018-01-25 | 주식회사 종근당 | Pharmaceutical composition comprising 5-α reductase inhibitor |
| ES2923438T3 (en) * | 2014-11-20 | 2022-09-27 | Serenity Pharmaceuticals Llc | Compositions comprising low doses of desmopressin in combination with an alpha-adrenergic receptor antagonist |
| WO2017058428A1 (en) * | 2015-09-30 | 2017-04-06 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
| SG11201805527QA (en) * | 2015-09-30 | 2018-07-30 | Wellesley Pharmaceuticals Llc | Composition for reducing the frequency of urination, method of making and use thereof |
| CN105238124B (en) * | 2015-11-16 | 2018-02-09 | 太仓东能环保设备有限公司 | A kind of antibacterial mastic powder |
| JP6294924B2 (en) | 2016-09-05 | 2018-03-14 | 株式会社Ｓｕｂａｒｕ | Vehicle travel control device |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2546399A (en) * | 1998-02-10 | 1999-08-30 | Yoshitomi Pharmaceutical Industries, Ltd. | Preparations with controlled release |
| US20020102309A1 (en) * | 1999-09-14 | 2002-08-01 | Jane C. I. Hirsh | Controlled release formulation for administration of an anti-inflammatory naphthalene derivative |
| DE10116978A1 (en) * | 2001-04-05 | 2002-10-10 | Merck Patent Gmbh | Kappa opiate agonists for the treatment of diseases of the bladder |
| US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| PL372395A1 (en) * | 2002-02-19 | 2005-07-25 | Pharmacia Corporation | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence |
| EP1552825A4 (en) * | 2002-06-07 | 2009-11-25 | Astellas Pharma Inc | Therapeutic agent for overactive bladder |
| US20040054008A1 (en) * | 2002-09-13 | 2004-03-18 | Tohru Araki | Medicament for treatment of nocturia |
| DE602004003172T2 (en) * | 2003-03-21 | 2007-09-27 | Dynogen Pharmaceuticals Inc., Waltham | METHOD FOR THE TREATMENT OF DISEASES OF THE LOWER HARN PATHS WITH ANTIMIC CARCINICS AND WITH MODULATORS OF THE ALPHA-2-DELTA SUB-UNIT OF THE CALCIUM CHANNEL |
| MXPA05010010A (en) * | 2003-03-21 | 2006-03-10 | Johnson & Johnson | Non-steroidal anti-inflammatory drug dosing regimen. |
| EP1627876A1 (en) * | 2004-08-20 | 2006-02-22 | Ferring B.V. | Heterocyclic condensed compounds useful as antidiuretic agents |
| EP2248524A3 (en) * | 2004-08-25 | 2011-03-09 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
| CA2612508A1 (en) * | 2005-06-17 | 2006-12-28 | Dynamis Therapeutics, Inc. | Treatment of inflammatory conditions |
| US20080085314A1 (en) * | 2005-07-29 | 2008-04-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
| AU2006284940B2 (en) * | 2005-09-02 | 2012-03-22 | Theravida, Inc. | Therapy for the treatment of disease |
| WO2010138441A1 (en) * | 2009-05-28 | 2010-12-02 | Aptapharma, Inc. | Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen |
| GB201003731D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
| US20120010294A1 (en) * | 2010-07-08 | 2012-01-12 | Dill David A | Compositions and methods for the inhibition of muscle contraction |
| US20120244221A1 (en) * | 2010-07-08 | 2012-09-27 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
-
2013
- 2013-03-13 MX MX2014011128A patent/MX2014011128A/en unknown
- 2013-03-13 BR BR112014020271A patent/BR112014020271A8/en not_active Application Discontinuation
- 2013-03-13 NZ NZ718163A patent/NZ718163A/en not_active IP Right Cessation
- 2013-03-13 AU AU2013235518A patent/AU2013235518B2/en not_active Ceased
- 2013-03-13 CA CA2866853A patent/CA2866853A1/en not_active Abandoned
- 2013-03-13 WO PCT/US2013/030901 patent/WO2013142197A1/en active Application Filing
- 2013-03-13 NZ NZ630471A patent/NZ630471A/en not_active IP Right Cessation
- 2013-03-13 NZ NZ712594A patent/NZ712594A/en not_active IP Right Cessation
- 2013-03-13 SG SG11201500408VA patent/SG11201500408VA/en unknown
- 2013-03-13 KR KR1020147029163A patent/KR20140134333A/en not_active Application Discontinuation
- 2013-03-13 RU RU2014142025A patent/RU2669565C2/en not_active IP Right Cessation
- 2013-03-13 JP JP2015501754A patent/JP2015510928A/en active Pending
- 2013-03-13 CN CN201380015062.3A patent/CN104302284A/en active Pending
- 2013-03-13 NZ NZ714288A patent/NZ714288A/en not_active IP Right Cessation
- 2013-03-13 MY MYPI2014702434A patent/MY174090A/en unknown
- 2013-03-13 CN CN201710373440.5A patent/CN107157991A/en active Pending
- 2013-03-13 EP EP13763764.1A patent/EP2827852A4/en not_active Withdrawn
- 2013-03-14 MX MX2014011129A patent/MX2014011129A/en unknown
- 2013-03-14 NZ NZ628079A patent/NZ628079A/en not_active IP Right Cessation
- 2013-03-14 SG SG11201500409SA patent/SG11201500409SA/en unknown
- 2013-03-14 JP JP2015501785A patent/JP2015510936A/en active Pending
- 2013-03-14 RU RU2016133305A patent/RU2016133305A/en not_active Application Discontinuation
- 2013-03-14 EP EP13763665.0A patent/EP2827851A4/en not_active Withdrawn
- 2013-03-14 MY MYPI2014702174A patent/MY175764A/en unknown
- 2013-03-14 AU AU2013235507A patent/AU2013235507B2/en not_active Ceased
- 2013-03-14 RU RU2014142066/15A patent/RU2599017C2/en not_active IP Right Cessation
- 2013-03-14 NZ NZ714662A patent/NZ714662A/en not_active IP Right Cessation
- 2013-03-14 CN CN201711086139.2A patent/CN107789626A/en active Pending
- 2013-03-14 KR KR1020177002422A patent/KR20170015537A/en active Application Filing
- 2013-03-14 CA CA2866755A patent/CA2866755A1/en not_active Abandoned
- 2013-03-14 WO PCT/US2013/031617 patent/WO2013142274A1/en active Application Filing
- 2013-03-14 KR KR20147024604A patent/KR20140134284A/en active Search and Examination
- 2013-03-14 BR BR112014020113A patent/BR112014020113A8/en not_active Application Discontinuation
- 2013-03-14 KR KR1020187038194A patent/KR20190003840A/en not_active Application Discontinuation
- 2013-03-14 CN CN201380015025.2A patent/CN104321056A/en active Pending
-
2014
- 2014-08-11 ZA ZA2014/05862A patent/ZA201405862B/en unknown
- 2014-08-21 ZA ZA2014/06146A patent/ZA201406146B/en unknown
- 2014-09-17 MX MX2019008817A patent/MX2019008817A/en unknown
-
2015
- 2015-05-27 HK HK18110965.0A patent/HK1251469A1/en unknown
- 2015-05-27 HK HK15105034.0A patent/HK1204553A1/en unknown
-
2016
- 2016-05-04 JP JP2016092868A patent/JP2016172752A/en active Pending
-
2017
- 2017-05-11 AU AU2017203139A patent/AU2017203139B2/en not_active Ceased
- 2017-05-15 AU AU2017203246A patent/AU2017203246B2/en not_active Ceased
- 2017-09-20 JP JP2017179685A patent/JP2018024693A/en active Pending
-
2018
- 2018-03-10 HK HK18103371.3A patent/HK1243921A1/en unknown
- 2018-05-15 JP JP2018093416A patent/JP2018138602A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ628079A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| BR112012019529A2 (en) | d-nitrosoglutathione reductase inhibitors | |
| MX2020010535A (en) | Methods of treating cancer. | |
| UY34112A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING A NEUROLEPTIC AGENT AND A SGLT2 INHIBITOR AND USES OF THE SAME | |
| BR112014011254A2 (en) | 2-thiopyrimidinones | |
| UY33530A (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES | |
| MX2016004741A (en) | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent. | |
| MY171526A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
| CL2015003561A1 (en) | Pharmaceutical composition for oral administration for use in the prevention and / or treatment of cardiovascular disease. | |
| MX2016016039A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof. | |
| MX2013002503A (en) | Combination of hdac inhibitors with thrombocytopenia drugs. | |
| MX2017003878A (en) | Pharmaceutical formulation for reducing bladder spasms and method of use thereof. | |
| CO6640306A2 (en) | Combination of xanthine oxidase inhibitors and angiotensin II receptor antagonists and their use | |
| CR20120617A (en) | COMBINATION OF XANTNA OXIDASA INHIBITORS AND ANTIGONISTS OF THE ANGIOTENSIN II RECEPTOR AND ITS USE | |
| TW201611830A (en) | Pharmaceutical formulation for reducing bladder spasms and method of use thereof | |
| CR20150411A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DEXKETOPROPHENE AND TRAMADOL | |
| UA59396U (en) | Use of compositions of non-steroid anti-inflammatory drugs and caffeine as antiexudative agents | |
| IT1397963B1 (en) | COMBINED THERAPEUTIC USE OF ORGANOSTAGNO (IV) AND INHIBITORS OF ISTONIC DEACETYLASES. | |
| MX345917B (en) | Analgesic compositions comprising quercetin and ketorolac. | |
| RS53597B1 (en) | Combination of a centrally-acting analgesic and a selective cyclooxygenase-2 inhibitor anti-inflammatory agent for the treatment of inflammation and pain in the veterinary field |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE OWNER HAS BEEN CORRECTED TO 3141002, WELLESLEY PHARMACEUTICALS, LLC, 3 VALLEY VIEW DRIVE, NEWTOWN PA 18940, US Effective date: 20160726 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2018 BY GRIFFITH HACK Effective date: 20170125 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2019 BY GRIFFITH HACK Effective date: 20180314 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2020 BY GH MELB PAT Effective date: 20190308 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2021 BY CPA GLOBAL Effective date: 20200424 |
|
| LAPS | Patent lapsed |